Serotonergic organization of the central nervous system

Psychiatria Danubina

Volumn 24, Issue SUPPL.3, 2012, Pages 326-330

  Timotijević, Ivana ^a   Stanković, Žana ^b   Todorović, Mirjana ^c   Marković, Srdjan Z ^a   Kastratović, Dragana A ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c Serbian Medical Society   (Serbia)

Author keywords

Amygdala nucleus; Hippocampus; Receptors; Serotonin

Indexed keywords

AMITRIPTYLINE; ARIPIPRAZOLE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; DOPAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; LOXAPINE; MIRTAZAPINE; MOCLOBEMIDE; NORADRENALIN; OLANZAPINE; PALIPERIDONE; PAROXETINE; PSILOCYBINE; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN RECEPTOR; SERTINDOLE; SERTRALINE; ZIPRASIDONE; ZOTEPINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

AMYGDALOID NUCLEUS; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; EXTRAPYRAMIDAL SYSTEM; GENERALIZED ANXIETY DISORDER; HIPPOCAMPUS; HUMAN; PREFRONTAL CORTEX; PSYCHOPHARMACOLOGY; SEROTONIN SYNDROME; SEROTONINERGIC SYSTEM; ARTICLE; DRUG EFFECT; METABOLISM; PHYSIOLOGY; SCHIZOPHRENIA;

AMYGDALA; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM; DEPRESSIVE DISORDER; DOPAMINE; HIPPOCAMPUS; HUMANS; MONOAMINE OXIDASE INHIBITORS; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 84872778625     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. th edn (DSM-IV). Washington, DC: American Psychiatric Press, 1994.
2. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. In: Annu. Rev. Med 2009;60:355-66.
3. Caspi A, Sugden K, Moffit TE et al. Influence of life stress on depression: moderation by a polymorphizm in the 5-HTTgene. Science 2003;301:195-216.
4. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103-8.
5. Duggal HS & Fetchko J. Serotonin Syndrome and Atypical Antipsychotics. Am J Psychiatry 2002;159:672-3.
6. Frazer A & Hensler JG. Understanding the neuroanatomical organizacion of serotonergic cells in the brain provides insight into the Junctions of this neurotransmitter. In Sigei GJ. Basic Neurochemistry 1999;212-24.
7. Freudenreich O, Cather C, Evins AE, Hendersin DC, Goff DC. Attitudes of schizophrenic outpatients toward psychiatric medication: relationship to clinical variables and insight. J Clin Psychiatry 2004;65(10):1372-6.
8. Garcia-Cabeza I, Gomez JC, Sacristan JA, Edgell E, Gonzalez De Chavez M. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry 2001;1:7.
9. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6.
10. Gilbertson MW, Shenton ME, Ciszewatski A. Smaller hippocampal volume predicts pathological vulnerability to psychological trauma. Nat Neurosci 2002;5(11):1242-7.
11. Gilmer TP, Dolder R., Lacro JP, Folsom P, Lindamer L, Garcia P, et al. Adherence to Treatment With Antipsychotic Medication and Health Care Costs Among Medicaid Beneficiaries With Schizophrenia. Am J Psychiatry 2004;161:692-9.
12. Hamilton S & Malone K. Serotonin syndrome treatment with paroxetine and risperidone (letter). J Clin Psychopharmacol 2000;20:103-5.
13. Hannon J & Hoyer D. Molecular biology of 5-HT" receptors. Behavior Brain Res 2008;195:198-213.
14. Jakovljevic M, Muck-Seler D, Kenfelj H, Plavsis V, Biocina S, Kastratovic D, Ljubicic DJ. Basal cortisol, dexamethasone suppression test and platelet 5-HT in recurrent (unipolar) major depression, schizophrenia and schizoaffective disorder. Psychiatr Danub 1991;3:389-414.
15. King MW. Serotonin. The Medical Byochemistry Page Indiana University School of Medicine 2009;12-01.
16. Meitzer HY & Massey B W. The role of serotonin receptors in the action of atypical antipsychotic drugs. Current Opinion in Pharmacology 2011;11:59-67.
17. Murphy BP, Chung YC, Park TW, McGorry PD. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006;88:5-25.
18. Nemeroff CB. Use of Atypical Antipsychotics in Refractory Depression and Anxiety J Clin Psychiatry 2005;66:13-21.
19. Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrhino F et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res 2006;83:53-63.
20. Rakic Ignjatovic A, Miljkovic B, Todorovic D, Timotijevic I, Pokrajac M. Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. Br J Clin Pharmacol 2009;67:199-208.
21. Rammes G, Eisensamer B, Ferrari U, Shapa M, Gimpl G, Gilling K et al. Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Mol Psychiatry 2004;9:846-58.
22. Reynolds GP, Yao Z, Zhang X, Sun J, Zhang Z. Pharmacogenetics of treatment in first-episode schtophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 2005;15:143-51.
23. Rich N, Herrel R, Lehner T et al. Interaction between the serotonin transporter gene (5-HTTLPR), stresful life events and risk of depression: a meta-analysis. JAMA 2009;301:2462-71.
24. Shin LM & Liberzon I. The neurocircitry of fear, stress, and anxiety disorder. Neuropsychopharmacol 2009;66:658-65.
25. nd edition). Cambridge University Press, Cambridge/New York; 2010; p. 1-30.
26. Stahl SM. Stahl's essential psychopharmacology, Third edition. New York, NY: Cambrige University Press; 2008.
27. Stanković Ž, Britvić D, Vukovic O, Ille T. Treatment compliance of outpatients with schizophrenia: patient's attitude, demographic, clinical and therapeutic variables. Psychiatria Danubina 2008;20:49-59.
28. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009;23:477-92.
29. Vezmar S, Miljkovic B, Vucicevic K, Timotijevic I, Prostran M, Todorovic Z, et al. Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression. J Pharmacol Sci 2009;110:98-104.
30. th edn (ICD-10). Geneva: WHO, 1994.